| Name | Title | Contact Details |
|---|
American Transplant Foundation is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VTI Corp. is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Field Safety Corp is a Guilford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UCM Digital Health (UCM) delivers an end-to-end digital first healthcare solution that combines a digital front door platform with a 24/7 emergency medicine treat, triage and navigation telehealth service – designed to lower costs, improve outcomes and provide a better patient experience. UCM Digital Health brings together clinical expertise, advanced technology and compassionate care to offer powerful advantages for insurers, brokers, employers, patients and providers. UCM Digital Health partners with insurers, employers, patients, providers, technology solutions companies – covering every corner of the healthcare ecosystem to deliver a complete, trusted, technology-based and data-driven healthcare solution. UCM Digital Health`s unique combination of digital front door platform plus emergency medicine triage and navigation expertise allows all care to begin digitally in one place. Located in Troy, New York, UCM Digital Health was founded in 2015 by emergency clinicians Keith Algozzine, PA-C and Michael Bibighaus, M.D., in an effort to combine healthcare and technology who continue to run the operations of the company.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.